Join PHG Foundation for this mastermind panel discussion on 28 January from 16:00 -16:40 – finishing in time for the day’s closing keynote trio, Sir John Bell, Dr Said Ismail and Dr Eric Topol
Beyond companion diagnostics - what next for ctDNA liquid biopsy in the NHS?
This session will discuss progress in developing applications of liquid biopsy for the early detection and management of cancer, prospects for implementation in the NHS, and associated policy issues this may pose.
Dr Mark Kroese (Director, PHG Foundation) - Chair
Prof Rachel Butler (Director, South West Genomic Laboratory Hub)
Dr Anca Oniscu (Clinical Lead Molecular Pathology, Royal Infirmary of Edinburgh)
Dr Nitzan Rosenfeld (Senior Group Leader, Cancer Research UK Cambridge Institute)
Dr Laura Blackburn (Head of Science, PHG Foundation)
Professor Rachel Butler
Rachel is the Head of the Bristol Genetic diagnostic laboratory, and Operational Director of the South West Genomics Laboratory Hub. She is currently the co-Chair of the National Genomic Test Directory Evaluation Group for Cancer. She was awarded an MBE in 2017 for services to Genomics in Wales and the UK.
Dr Nitzan Rosenfeld
Nitzan leads a translational research group at the CRUK Cambridge Institute, which focuses on the application of ctDNA as a tool for cancer diagnostics and non-invasive genomics. In 2014, Nitzan co-founded Inivata, a clinical cancer genomics company that aims to harness the emerging potential of ctDNA analysis. In 2013 Nitzan received the CRUK Future Leaders in Cancer Research Prize and he was awarded the Foulkes Foundation Medal from the British Academy of Medical Sciences in 2015.
Dr Anca Oniscu
Anca is a Consultant Pathologist and the Clinical Lead for Molecular Pathology at the Royal Infirmary of Edinburgh, and the National Clinical Lead for Molecular Pathology for NHS Scotland.